October 11-13, 2023

European Committee of Treatment and

Research in Multiple Sclerosis

October 26-28, 2022

European Committee of Treatment and

Research in Multiple Sclerosis

European Committee of Treatment and

Research in Multiple Sclerosis

Ofatumumab – B Cell Therapy
Ofatumumab Efficacy & Safety

Long-term Effect of Ofatumumab on Serum Immunoglobulin Levels in Patients With Relapsing Multiple Sclerosis

Wiendl H. et al
Poster: P709
Abstract

Efficacy of Ofatumumab on Microglial Activity and Brain Iron in Patients With Relapsing Forms of Multiple Sclerosis: Results From a 9-Month Study

Singhal T. et al
Poster: P179
Abstract

Evaluating Ofatumumab Excretion in Breastmilk of Women With RMS: Phase 4 Study Design

Hellwig K. et al
Poster: P1648
Abstract

COVID-19 Outcomes and Seropositivity Rates Following SARS-CoV-2 Vaccine and/or Infection in Ofatumumab-treated RMS Patients: Data from the ALITHIOS Open-label Extension Study

Wiendl H. et al
Poster: P288
Abstract

KAIROS: A Non-Interventional Study of Ofatumumab in Patients With Relapsing Remitting Multiple Sclerosis Who Previously Received Another Disease-Modifying Therapy

Bischof F. et al
Poster: P1590
Abstract

Immune Response to SARS-CoV-2 mRNA Booster Vaccinations in Relapsing Multiple Sclerosis Patients Treated With Ofatumumab s.c.– Final Results From the Open-label Multicenter KYRIOS trial

Ziemssen T. et al
Poster: P316
Abstract

Durability of Immune Response to COVID-19 Vaccines in Persons with MS Patients on B-Cell Depleting Therapy

Flanagan WS. et al
Poster: P277
Abstract

Assessment of Patients' Experiences With Ofatumumab in Multiple Sclerosis: Findings From a Market Research Survey Conducted in the Netherlands

Hengstman G. et al
Poster: P1640
Abstract

Journey of MS Patients in Turkey; A Questionnaire-based Survey - Injection Use Satisfaction

Tutuncu M. et al
Poster: P1210
Abstract

Characterizing up to 2 years Of Ofatumumab Onboarding And Utilization Among Real-World Relapsing Multiple Sclerosis Patients in Australia - The EAFToS Secondary Use of Data Study

Van der Walt A. et al
Poster: P746
Abstract

Employing Novel Indirect Treatment Comparison Methodologies to Differentiate the Efficacy of Ofatumumab and Other High Efficacy Therapies versus Orally Administered Disease Modifying Therapies for Relapsing Multiple Sclerosis

Butzkueven H. et al
Poster: P755
Abstract

Changes in Immunoglobulin in Patients with Multiple Sclerosis Treated with Anti-CD20 Monoclonal Antibodies

Vollmer B. et al
Poster: P286
Abstract

Real-world Effectiveness, Tolerability and Safety of Ofatumumab at 12-month Follow-up

Amin M. et al
Poster: P1559
Abstract

OLIKOS Study: 6-Month Interim Efficacy and Safety in Patients with Relapsing Multiple Sclerosis who Switched to Subcutaneous Ofatumumab from Intravenous Anti-CD20 Therapies

Hua L. et al
Poster: P784
Abstract
Remibrutinib – BTK inhibitor
Remibrutinib Safety

Remibrutinib Ameliorates CNS Autoimmune Disease - Insights From EAE

Kieseier B. et al
Poster: P1480
Abstract

Meta-Analysis For Neurofilament Light chain (NfL) as Biomarker in Mouse Experimental Autoimmune Encephalomyelitis (EAE) Studies

Bigaud M. et al
Poster: P118
Abstract
Siponimod - S1P Receptor Modulator
Siponimod Efficacy & Safety

Clinical And Vocational Relevance of SDMT Changes: 1-Year Follow-Up Results (Data) on the SDMT-PRO Study Population

Penner IK. et al
Poster: P1200
Abstract

Clinically Defined Conversion to SPMS Approaching Objectively Data-driven Incidence in RWE in the Czech Republic in Years 2016-2021

Horakova D. et al
Poster: P401
Abstract

Preventing Oxidative Stress-Induced Changes in Mitochondrial Dynamics - Investigation of Neuroprotective Effects of S1P Receptor Modulators Ex Vivo Using a Semi-Automated Live Imaging Set-Up

Anderhalten L. et al
Poster: P388
Abstract
Fingolimod Efficacy

Innate and B cell Responses in MS patients on Fingolimod and Ocrelizumab Following 2 Doses of SARS-CoV-2 mRNA Vaccine

Saxena S. et al
Poster: P1471
Abstract
MS Treatment & Care
MS Management

An Agnostic Approach for Multiple Sclerosis Disease States and Prognosis Using Artificial Intelligence: Four Clinical States Allow Description of The Disease and its Probabilities for Evolution

Ganjgahi H. et al
Oral Presentation: O153
Abstract

Prognostic Factors of Future Disability Accrual and Improvement in Multiple Sclerosis

Wiendl H. et al
Oral Presentation: O062
Abstract

Measuring Fatigue in Multiple Sclerosis Clinical Trials: Why Patient Reported Outcome Measure Choice is not Immaterial When Measuring Change

Hobart J. et al
Poster: P479
Abstract

Incidence Of COVID-19 In Patients With Multiple Sclerosis Who Received SARS-Cov-2 Vaccines And Are Under Treatment With High-Efficacy Therapies In Argentina

Carnero Contentti E. et al
Poster: P1573
Abstract

A Novel Eye Movement Biomarker Application for Monitoring Multiple Sclerosis Disease Progression

Giacomini PS. et al
Poster: P1427
Abstract

Spanish Society Of Neurology Consensus and Recommendations On Multiple Sclerosis Treatment

Oreja-Guevara C et. al
Poster: P1639
Abstract

Burden Of Treatment and Quality Of Life In Relapsing Remitting Multiple Sclerosis Patients Under Early High Efficacy Therapy In Argentina: Data From The Argentinean Registry

Rojas JI et. al
Poster: P1191
Abstract

Clinical Outcomes and Treatment Strategy of Multiple Sclerosis In China: Results From A Real-World Cross-Sectional Survey

Wenhao W. et al
Poster: P453
Abstract

Journey of MS Patients in Turkey; A Questionnaire-Based Survey – Burden of MS

Demir S. et al
Poster: P1197
Abstract

Quantitative Myelin Imaging is Associated With Eomesodermin Expressing CD4+ Th-Cells in Secondary Progressive Multiple Sclerosis

Schneider R. et al
Poster: P1342
Abstract

Serum-Neurofilament Light Chain Levels in Secondary Progressive Multiple Sclerosis Are Associated With Grey Matter Destruction Characterized By Relaxation Rates

Schneider R. et al
Poster: P210
Abstract

Similarities in Brain Damage Across the Spectrum of Multiple Sclerosis

Bermel R. et al
Poster: P375
Abstract

MLR ID: 311152

Ofatumumab
Efficacy and safety

Longer-term Safety and Efficacy of Ofatumumab in Recently Diagnosed and Treatment Naïve Patients is Consistent With the Overall Population in the ALITHIOS Open-label Extension Study

Gartner J. et al
Poster: P052
Abstract

Compliance and Persistence With Ofatumumab Treatment in Patients With Relapsing Multiple Sclerosis in Clinical Trials for up to 4 Years

Alvarez E. et al
Poster: P734
Abstract

Serum Neurofilament Light Chain Levels and NEDA-3 Status With Ofatumumab Treatment in RMS Patients: Longer-term Analysis From ASCLEPIOS I/II and ALITHIOS

Kuhle J. et al
Poster: P1198
Abstract

Efficacy of Early Ofatumumab Versus Late-Switch From Teriflunomide: Subgroup Analysis of the ALITHIOS Open-Label Extension Study by Prior Disease Modifying Therapy Exposure and Age

Cohen J. et al
Poster: P1210
Abstract

Earlier Ofatumumab Treatment may Reduce Disease Progression and Relapses for Patients With Relapsing-remitting Multiple Sclerosis: Results From a Cost-Consequence Model

Green L. et al
ePoster: EP1105
Abstract
Preclinical Studies

Comparative Pharmacology of Ofatumumab versus Ocrelizumab in Humanised-CD20 Transgenic Mice

Bigaud M. et al
Poster: P298
Abstract
Vaccination

Open-label, Multicentre, Phase 4 Study Assessing Immune Response to Influenza Vaccine in Patients With Relapsing Multiple Sclerosis Treated With Ofatumumab: Interim Results

Steingo B. et al
Poster: P1211
Abstract
Siponimod
Efficacy and safety

Siponimod Stabilises Physical Disability Scores in People Living With Secondary Progressive Multiple Sclerosis after 2 Years of Treatment: Analysis From the Novartis Global Managed Access Program

De las Heras V. et al
Poster: P325
Abstract

Disability Status and Cognitive Functioning in Patients With Advancing Multiple Sclerosis Switching to Siponimod: Interim Results of the EXCHANGE Study

Fox R. et al
Poster: EP1146
Abstract

Treatment Satisfaction With Siponimod in Patients With Advancing Relapsing Multiple Sclerosis: Interim Results of the EXCHANGE Study

Cohan S. et al
Poster: EP1145
Abstract
Real world Studies

AMASIA Study: Real-world Data on MS Therapy Optimization With Siponimod

Hoffman O. et al
Poster: P448
Abstract

Novel Generation of Real World Evidence through MSGo, a Digital Support Program Supporting the Use of Siponimod in Secondary Progressive Multiple Sclerosis Patients in Australia

Hardy T. et al
ePoster: EP1137
Abstract
Patient-reported outcomes

A Large Cohort Study Evaluating Patient Reported Perspectives on Disease Burden and Early Signs of Progression in Multiple Sclerosis in Germany (MSPerspectives)

Bayas A. et al
Poster: P109
Abstract

Patient-reported Outcomes in Multiple Sclerosis Clinical Trials: Measurement Lessons From the EXPAND Study

Hobart J. et al
ePoster: EP1234
Abstract
Preclinical Studies

Siponimod Favours Expression of Less Pro-inflammatory, Alternatively Activated Microglia in a Microglia Repopulation Model of Progressive Multiple Sclerosis - Implication for Neuroprotection

Heitmann N. et al
Poster: P132
Abstract
Fingolimod
Efficacy and safety

Long-term Efficacy and Safety of Fingolimod in Paediatric Multiple Sclerosis Patients: Analysis of PARADIGMS Study up to 6 years of Treatment

Deiva K. et al
Oral Presentation: O069
Abstract

Deciphering Multiple Sclerosis Disability Progression in the Elderly: A Multicenter Cohort Study

Ouallet J. et al
Poster: P456
Abstract

Myeloid-Derived Suppressor Cells are Good Biomarkers of Fingolimod Efficacy in Multiple Sclerosis

Camacho-Toledano C. et al
ePoster: EP1022
Abstract
Remibrutinib
Preclinical Studies

Remibrutinib Inhibits Neuroinflammation Driven by B Cells and Myeloid Cells in Preclinical Models of Multiple Sclerosis

Nuesslein-Hildesheim B. et al
Poster: P134
Abstract

Remibrutinib, a Novel Bruton Tyrosine Kinase Inhibitor, Exhibits Improved Target Selectivity and Potency in vitro

Pulz R. et al
ePoster: EP0896
Abstract
MS & COVID-19

Humoral Immune Response to COVID-19 mRNA Vaccines in Patients With Relapsing Multiple Sclerosis Treated With Ofatumumab

Hendin B. et al
Poster: P345
Abstract

Spike Antibody Seroconversion and Breadth Following SARS-CoV-2 Vaccination in Australian People With Multiple Sclerosis

Brilot F. et al
Poster: P564
Abstract

KYRIOS clinical trial: Tracking the immune response to SARS-CoV-2 mRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c.

Ziemssen T. et al
Poster: P711
Abstract

Preserved T Cell but Attenuated Antibody Response in MS Patients on Fingolimod and Ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA Vaccine

Saxena S. et al
Poster: P713
Abstract

COVID-19 Outcomes in Fingolimod- or Siponimod – Treated Patients: Clinical Trial and Post Marketing Cases

Berger J. et al
Poster: P726
Abstract

Durability of Immune Response to COVID-19 Vaccines in MS Patients on B-Cell Depleting Therapy

Straus Farber R. et al
ePoster: EP1270
Abstract
Innovation & MS management
Biomarkers

A Novel Signature of Lipoxin A4 and Prostaglandin E2 in Plasma Associated With Disease Severity in Patients With Relapsing-remitting And Secondary Progressive Multiple Sclerosis

Broos J. et al
Poster: P249
Abstract
Data & Digital

Existing Claims-based Algorithm may Overestimate Relapses in Multiple Sclerosis (MS) Patients using Infusible Disease Modifying Therapies (DMTs) that Require Steroid Premedication

Hersh C. et al
Poster: P102
Abstract

Multiple Sclerosis Disease States as Identified by Unsupervised Machine Learning on Multimodal Longitudinal Patient Trajectories

Ganjgahi H. et al
Poster: P1208
Abstract

MSGo, an Australian digital support program for patients with Multiple Sclerosis prescribed Fingolimod, Ofatumumab and Siponimod

Hatter L. et al
ePoster: EP0883
Abstract
Patient-reported outcomes

RelevanceofSDMT changesin thedailylifeofmultiple sclerosispatients–a real worldstudy

Penner IK. et al
Poster: P107
Abstract

Characterization of Patient and Treatment Characteristics in SPMS and at Risk for SPMS Patients in Clinical Routine: Final Results From the PANGAEA 2.0 EVOLUTION Study

Baufeld C. et al
ePoster: EP1198
Abstract
MS Management

MAGNON – Implementation and Contribution of Lublin Criteria and Quantitative MRI-Analysis for Daily Clinical Routine of MS Patients

Hoffmann O. et al
Poster: P598
Abstract

Evaluation of the Use of High Efficacy Treatments (HETs) in Patients With Relapsing-remitting Multiple Sclerosis in Argentina

Alonso R. et al
Poster: EP1050
Abstract

SPMS Diagnosis: A Canadian Practice Audit

Vosoughi R. et al
Poster: EP1185
Abstract

MLR ID- 247881

October 13-15,2021
 

MRI Activity versus Relapses as Markers of Disease Activity in SPMS: Data from Real World and Pivotal Clinical Studies

E-poster:P001
Abstract

Discordance Between Neurologists and People Living With Multiple Sclerosis on the Perception of the Presence and Burden of Cognitive Impairment

E-poster:P079
Abstract

Using historical relapse rates for the design of an innovative Phase 3 study with ofatumumab and siponimod in paediatric multiple sclerosis

E-poster:P097
Abstract

Innovative Phase 3 NEOS study design evaluating efficacy and safety of ofatumumab and siponimod versus fingolimod in paediatric multiple sclerosis

E-poster:P102
Abstract

Development of Your MS Questionnaire: A Patient Completed Digital Tool to Monitor Multiple Sclerosis Disease Symptoms and Their Impact on People’s Life

E-poster:P119
Abstract

Characterization of the gait in patients with relapsing–remitting multiple sclerosis and secondary progressive multiple sclerosis measured by FeetMe® integrated sensor insole system: Results of the interim analysis

E-Poster:P222
Abstract

Patient-Reported Outcomes Measures for Multiple Sclerosis: Patient Insights on Fatigue, Cognition, Pain and Depression, and their Interconnectivity

E-poster:P234
Abstract

Economic impact and clinical profile of the Secondary Progressive Multiple Sclerosis (SPMS) patient: the DISCOVER study

E-poster:P274
Abstract

The societal cost and burden of multiple sclerosis in Spain

E-poster:P276
Abstract

Cost-effectiveness of ofatumumab in comparison with other disease modifying therapies and best supportive care for the treatment of relapsing-remitting multiple sclerosis in Canada

E-poster:P281
Abstract

Evaluating Perceptions of Ofatumumab in Multiple Sclerosis via Social Media Listening – Early 6 Months Post Approval Data

E-Poster:P310
Abstract

Effect of ofatumumab on brain volume loss vs historical placebo in relapsing multiple sclerosis

E-poster:P533
Abstract

Siponimod preserves retinal thickness, a marker of neurodegeneration, in patients with SPMS: Findings from the EXPAND OCT substudy

E-poster:P545
Abstract

Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the EXPAND Study

E-Poster:P637
Abstract

Tracking the immune response to SARS-CoV-2 mRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS clinical trial)

E-poster:P660
Abstract

Safety and Tolerability of Conversion to Siponimod With and Without Titration in Patients with Advancing Forms of RMS: Interim Results of the Phase 3b EXCHANGE Study

E-poster:P672
Abstract

Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying as Hispanic from the Phase 3 EXPAND Study

E-poster:P696
Abstract

Central versus peripheral drug exposure ratio, a key parameter for therapeutic efficacy of S1P receptor modulators in SPMS

E-poster:P721
Abstract

Estimating long-term effect of siponimod on disability progression versus virtual placebo in SPMS using RPSFT model: EXPAND data up to 7 years

E-poster:P745
Abstract

Design and Rationale for an Open-label Multicenter Phase 4 Study Assessing Immune Response to COVID-19 Vaccine in Patients With RMS Treated With Ofatumumab

E-poste:P777
Abstract

Assessing the immune response to SARS-CoV-2 mRNA vaccines in patients with secondary progressive multiple sclerosis treated with siponimod (AMA-VACC clinical trial)

E-poster:P810
Abstract

Effectiveness and safety of early high-efficacy vs. escalation therapy in relapsing-remitting multiple sclerosis in Argentina

E-poster:P827
Abstract

High prevalence of intolerability with interferon beta and glatiramer acetate in patients with MS

E-poster:P847
Abstract

Novel Generation of Real World Evidence through MSGo, a Digital Support Program Supporting the Use of Siponimod in Secondary Progressive Multiple Sclerosis Patients in Australia

E-poster:P864
Abstract

Multiple Sclerosis Patients Initiating Ofatumumab in the Real-World: 6 Months Data

E-poster:P874
Abstract

Estimating the long-term clinical and societal outcomes of ofatumumab compared with teriflunomide and evaluating the impact of immediate vs delayed high efficacy therapy in treating patients with relapsing multiple sclerosis in Spain

E-Poster:P913
Abstract

Network meta-analysis of disease-modifying therapies for relapsing multiple sclerosis based on confirmed disability progression: Investigating the influence of cross-trial differences in endpoint definition

E-Poster:P914
Abstract

Relapse reduction by disease-modifying therapies for relapsing multiple sclerosis: A network meta-analysis

E-Poster:P919
Abstract

First-hand experience with ofatumumab at ASCLEPIOS study sites in Europe

E-poster:P920
Abstract

Effect of ofatumumab on serum immunoglobulin levels and infection risk in patients with relapsing multiple sclerosis over 3.5 years

E-poster:P931
Abstract

Early Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of MS: Interim Analysis of a 9-month Study

E-poster:P966
Abstract

Outcomes of COVID-19 in patients with relapsing multiple sclerosis receiving ofatumumab: Data from the ALITHIOS study and post marketing surveillance

E-poster:P982
Abstract

MLR ID: 179427

September 11-13,2020 Presentations
 

Prediction of MS disability status in Japanese claims database using principal component analysis

eposter: P0133
Abstract

Validation of the FeetMe® system versus GAITRite® to assess gait characteristics in patients with multiple sclerosis: Subpopulation analysis

eposter: P0182
Abstract

Immune cell profiles and clinical and safety outcomes with fingolimod in the 12 month FLUENT study of patients with relapsing multiple sclerosis

eposter: P0213
Abstract

OLIKOS study design: Exploring maintained ofatumumab efficacy in relapsing MS patients who transition from intravenous anti-CD20 therapy

eposter: P0222
Abstract

Safety and tolerability of conversion to siponimod in patients with relapsing multiple sclerosis: Interim results of the EXCHANGE study

eposter: P0233
Abstract

MS progression discussion tool (MSProDiscussTM) usability and usefulness assessment in clinical practice in chile

eposter: P0885
Abstract

Investigation of lesion volume dynamics in MS patients as detected by Voxel-Guided Morphometry – A multi center study

eposter: P0596
Abstract

Consensus guidelines for the timely detection and diagnosis of disease progression in multiple sclerosis patients

eposter: P0248
Abstract

MAGNON – Implementation and value of lublin criteria and quantitative MRI analysis in clinical routine care of MS patients

eposter: P0603
Abstract

QUANTUM – Quantitative and standardized imaging in daily clinical routine of multiple sclerosis patients

eposter: P0629
Abstract

Recommendations for the coordination of Neurology and Neuroradiology departments in the management of patients with multiple sclerosis

eposter: P0631
Abstract

Social Listening: Digital Profile of the multiple sclerosis patient in Mexico

eposter: P0665
Abstract

The Dutch MS Patient Voice Survey: The search for information

eposter: P0667
Abstract

A First Look at the characteristics of patients with multiple sclerosis initiating siponimod therapy in the United States

eposter: P0835
Abstract

Baseline characteristics of AMASIA: first real world data of siponimod treated patients with secondary progressive multiple sclerosis

eposter: P0839
Abstract

Clinical course and therapeutic management of secondary progressive multiple sclerosis in France: A retrospective real-world multicentric observational study (ODYSSEP Study)

eposter: P0855
Abstract

PANGAEA 2.0 EVOLUTION: Unraveling patient and treatment characteristics for SPMS and at risk for SPMS patients in clinical routine

eposter: P0896
Abstract

Preliminary data from the 5-year Hungarian fingolimod registry

eposter: P0898

Economic impact of the secondary progressive multiple sclerosis in Spain: Interim analysis of the DISCOVER study

eposter: P1024
Abstract

The Dutch MS patient voice survey: Impact of disease on daily life

eposter: P1057
Abstract

The Dutch MS patient voice survey: Impact of multiple sclerosis on daily life activities; characteristics of disease phenotype and treatment

eposter: P1085
Abstract

Treatment failure in patients with multiple sclerosis initiating frequently used first line therapies

eposter: P0409
Abstract

Patient and healthcare professional perspectives of immune dynamics and MS disease-modifying therapies mode of action throughout COVID-19 pandemic

eposter: LB1174
Abstract

Update on the risk estimates of progressive multifocal leukoencephalopathy related to fingolimod

Oral Presentation: FC02.02
Abstract

Cumulative update on pregnancy outcomes after fingolimod treatment in patients with multiple sclerosis

eposter: P1118
Abstract

High plasma glial fibrillary acidic protein levels predict the disability milestone EDSS 7 in non-active secondary progressive multiple sclerosis

Oral Presentation: FC04.03
Abstract

Modeling a long-term virtual placebo arm for the SPMS population in the EXPAND study: Comparing different statistical methods

eposter: P0013
Abstract

Sustained reduction of disability and cognitive decline with long-term siponimod treatment in patients with active SPMS: EXPAND data up to 5 years

eposter: P0238
Abstract

Dual mode of action of siponimod in secondary progressive multiple sclerosis: A hypothesis based on the relevance of pharmacological properties

eposter: P0317
Abstract

Mouse astrocytes exhibit agonist-induced functional S1P1 receptor antagonism

eposter: P0357
Abstract

Impact of siponimod on myelination as assessed by MTR across SPMS subgroups: Post hoc analysis from the EXPAND MRI substudy

eposter: P0587
Abstract

Effect of siponimod on cognitive processing speed in SPMS patients with active and non-active disease

eposter: P0806
Abstract

MSProDiscussTM is a useful tool to aid discussion of multiple sclerosis disease progression: Results from a large, real-world qualitative survey

eposter: P0885
Abstract

Assessing the temporal relationship of serum neurofilament light (NfL) and subclinical disease activity: Findings from APLIOS trial

eposter: P0028
Abstract

Dose-dependent tolerability of intravenous and subcutaneous ofatumumab in clinical studies

eposter: P0316
Abstract

Safety experience with extended exposure to ofatumumab in patients with relapsing multiple sclerosis from phase 2 and 3 clinical trials

eposter: P0234
Abstract

Rapid and sustained B-cell depletion with ofatumumab: Population pharmacokinetic B-cell modeling in relapsing multiple sclerosis patients

eposter: P0396
Abstract

Effect of anti-CD20 antibody-mediated B-cell depletion on susceptibility to Pneumocystis infection in mice

eposter: P0322
Abstract

Long-term safety, compliance, and effectiveness of ofatumumab in patients with relapsing multiple sclerosis: The ALITHIOS Phase 3b study

eposter: P0218
Abstract

Effect of anti-CD20 antibody-induced B-cell depletion on the susceptibility to Streptococcus pneumoniae infections

eposter: P0321
Abstract

Benefit-risk of Ofatumumab in Treatment-naïve Early Relapsing Multiple Sclerosis Patients

eposter: P0192
Abstract

Efficacy and safety of ofatumumab versus placebo in relapsing multiple sclerosis patients in Japan and Russia: results from the Phase 2 APOLITOS study

eposter: P0209
Abstract

Baseline serum neurofilament light levels have prognostic value for on-study MRI activity: Results from ASCLEPIOS trials

eposter: P0033
Abstract

Serum immunoglobulin levels and infection risk in the Phase 3 trials of ofatumumab in relapsing multiple sclerosis

eposter: P0236
Abstract

Protective and Remyelinating Potential of Siponimod in a Xenopus Model of Demyelination and a Mouse Model of Experimental Autoimmune Encephalomyelitis

eposter: P0991
Abstract

MLR ID: 122819

Cookie Settings